[A23-79] Cipaglucosidase alfa (Pompe disease) – Benefit assessment according to § 35a Social Code Book (SGB) V
Last updated 01.02.2024
Project no.:
A23-79
Commission:
Commission awarded on 01.08.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Long-term enzyme replacement therapy used in combination with the enzyme stabilizer miglustat for the treatment of adults with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency)
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-79
| Project no. | Title | Status |
|---|---|---|
| A23-133 | Cipaglucosidase alfa (Pompe disease) – Addendum to Project A23-79 | Commission completed |
Federal Joint Committee (G-BA)
2024-02-01 A G-BA decision was published.